CRISAL Study:Cancer Risk In Secreting Adrenal Lesions

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Roma La Sapienza

About this trial

The aim of the present study is to report the cancer risk in secreting adrenal lesions. Secondary aims: to compare the incidence of cancer in secreting versus non-secreting adrenal lesions, in order to evaluate whether adrenal hormone activity can be considered an independent predictive indicator of malignancy; compare intraoperative and 30-day postoperative outcomes of patients undergoing adrenalectomy for secreting adrenal lesions versus non-secretoring lesions; regardless of the type of adrenal lesion, identify if there is one MIS adrenal approach that is superior to the others in terms of intra- and postoperative outcomes.

Eligibility criteria

Qualifiers

Patients undergoing elective adrenalectomy;

Patients aged ≥ 18 years

Acceptance of informed consent

Disqualifiers

Patients aged ≤ 18 years

Pregnant patients

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

300 Participants
are grouped into 2 trial groups

Sponsors and collaborators

University of Roma La Sapienza

Lead sponsor

IRCCS San Raffaele

Sponsor institution